Ascendis has been a terrible investment, and now everything hinges on the sale of its crown jewel
Pharmaceuticals and healthcare business Ascendis has not had a good year. In fact, it does not have a good three-or five-year history.
The business, which listed on the JSE in November 2013, was bankrolled by well-known private equity team Coast2Coast, which, aside from being a material shareholder in Ascendis, also drove the highly ambitious acquisition strategy.A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, Morningstar financial data, and digital access to the Sunday Times and Times Select.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: